CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019

On February 27, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that clinical and preclinical results for CX-2009, a CD166 targeting Probody Drug Conjugate, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 from March 29 – April 3 in Atlanta, Georgia (Press release, CytomX Therapeutics, FEB 27, 2019, View Source [SID1234533794]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors
Session: Late-Breaking Research: Immunology 2
Date and Time: Tuesday, April 2, 2019 8:00 a.m. – 12:00 p.m.
Location: Exhibit Hall B, Poster Section 42; Poster Board 3
Abstract Number: 7669

Title: A Probody Drug Conjugate Targeting CD166 (ALCAM) Enhances Preclinical Antitumor Activity of a Probody Therapeutic Targeting PD-1
Session Category: Immunology
Session Title: Combination Immunotherapies 2
Date and Time: Tuesday, April 2, 2019 8:00 a.m. – 12:00 p.m.
Location: Exhibit Hall B, Poster Section 23; Poster Board 12
Abstract Number: 3202

Title: CD166-DM4 Probody Drug Conjugate (CX-2009) Treatment of 198 Patient-derived Xenograft Models (PDX) in a Mouse Clinical Trial Format
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates: New Agents and Technologies
Date and Time:Sunday, March 31, 2019 1:00 p.m. – 5:00 p.m.
Location: Exhibit Hall B, Poster Section 9; Poster Board 3
Abstract Number: 212